What is Heron Therapeutics Inc's earnings per share (EPS)?

Heron Therapeutics Inc (HRTX) reported diluted earnings per share of $-0.12 for fiscal year 2025. This represents a -33.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Heron Therapeutics Inc Financials

HRTX

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Heron Therapeutics Inc (HRTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HRTX FY2025 2026-05-11

Gross-margin reset and a lighter R&D load have nearly erased the operating loss, while working capital still absorbs cash.

Over the last two years, gross margin moved from 48.8% to 73.3%, and that step-up did most of the work in shrinking the operating loss. Yet cash conversion still lags because inventory and receivables reached $182.3M, while interest expense rose to $9.6M; the business is much closer to operating break-even than to balance-sheet ease.

This no longer looks like a company dominated by research spend: R&D fell from $39.1M to $12.4M, shifting the operating story toward commercialization discipline. That matters because a business can trim losses faster than it grows sales when lower research spending and higher gross profit arrive together.

The balance sheet is still thinly capitalized: equity is only $14.3M against liabilities of $241.5M. Short-term liquidity is less strained than that leverage picture implies because the current ratio is 2.5x, but free cash flow remained -$27.9M.

Financial Health Signals

Financial Health Score 46/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Heron Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-9.17

Heron Therapeutics Inc scores -9.17, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($81.1M) relative to total liabilities ($241.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Heron Therapeutics Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

1.38x

For every $1 of reported earnings, Heron Therapeutics Inc generates $1.38 in operating cash flow (-$27.6M OCF vs -$20.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-0.3x

Heron Therapeutics Inc earns $-0.3 in operating income for every $1 of interest expense (-$2.5M vs $9.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$154.9M

YoY+7.4%

5Y CAGR+11.8%

Heron Therapeutics Inc generated $154.9M in revenue in fiscal year 2025. This represents an increase of 7.4% from the prior year.

EBITDA

-$224K

YoY+97.5%

Heron Therapeutics Inc's EBITDA was -$224K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 97.5% from the prior year.

Net Income

-$20.0M

YoY-42.9%

Heron Therapeutics Inc reported -$20.0M in net income in fiscal year 2025. This represents a decrease of 42.9% from the prior year.

EPS (Diluted)

$-0.12

YoY-33.3%

Heron Therapeutics Inc earned $-0.12 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 33.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$27.9M

YoY-15.2%

Heron Therapeutics Inc generated -$27.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 15.2% from the prior year.

Cash & Debt

$28.6M

YoY+11.0%

5Y CAGR-22.9%

10Y CAGR-9.2%

Heron Therapeutics Inc held $28.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

189M

YoY+23.8%

5Y CAGR+15.6%

10Y CAGR+17.9%

Heron Therapeutics Inc had 189M shares outstanding in fiscal year 2025. This represents an increase of 23.8% from the prior year.

Margins & Returns

Gross Margin

73.3%

YoY+0.1pp

5Y CAGR+14.1pp

Heron Therapeutics Inc's gross margin was 73.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.1 percentage points from the prior year.

Operating Margin

-1.6%

YoY+6.3pp

5Y CAGR+255.8pp

Heron Therapeutics Inc's operating margin was -1.6% in fiscal year 2025, reflecting core business profitability. This is up 6.3 percentage points from the prior year.

Net Margin

-12.9%

YoY-3.2pp

5Y CAGR+243.5pp

Heron Therapeutics Inc's net profit margin was -12.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 3.2 percentage points from the prior year.

Return on Equity

-139.5%

5Y CAGR-43.4pp

10Y CAGR-56.9pp

Heron Therapeutics Inc's ROE was -139.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$12.4M

YoY-25.5%

5Y CAGR-41.0%

10Y CAGR-14.7%

Heron Therapeutics Inc invested $12.4M in research and development in fiscal year 2025. This represents a decrease of 25.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$317K

YoY-81.4%

5Y CAGR-45.9%

10Y CAGR-11.6%

Heron Therapeutics Inc invested $317K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 81.4% from the prior year.

HRTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$154.9M+7.4%	$144.3M+13.6%	$127.0M+18.0%	$107.7M+24.7%	$86.3M-2.6%	$88.6M
Cost of Revenue	$41.3M+7.0%	$38.6M-40.6%	$65.1M+18.6%	$54.9M+19.2%	$46.0M+27.2%	$36.2M
Gross Profit	$113.6M+7.5%	$105.6M+70.6%	$61.9M+17.3%	$52.8M+30.9%	$40.3M-23.1%	$52.4M
R&D Expenses	$12.4M-25.5%	$16.7M-57.4%	$39.1M-52.7%	$82.7M-36.8%	$130.8M-25.0%	$174.5M
SG&A Expenses	$54.6M+2.3%	$53.4M-18.8%	$65.8M+5.7%	$62.2M+55.0%	$40.2M-4.9%	$42.2M
Operating Income	-$2.5M+78.0%	-$11.5M+89.6%	-$110.6M+36.7%	-$174.7M+19.8%	-$217.8M+4.5%	-$228.2M
Interest Expense	$9.6M+59.2%	$6.0M+55.9%	$3.9M+56.3%	$2.5M+2.7%	$2.4M+26.8%	$1.9M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$20.0M-42.9%	-$14.0M+87.4%	-$111.0M+39.0%	-$182.0M+17.6%	-$221.0M+2.8%	-$227.3M
EPS (Diluted)	$-0.12-33.3%	$-0.09+88.8%	$-0.80+52.1%	$-1.67+25.4%	$-2.24	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$34.7M-14.5%	$40.6M+6.2%	$38.2M+2.7%	$37.2M-4.4%	$38.9M-4.6%	$40.8M+24.3%	$32.8M-8.9%	$36.0M
Cost of Revenue	$10.6M-4.3%	$11.1M-6.7%	$11.9M+20.9%	$9.9M+16.6%	$8.5M-17.3%	$10.2M+8.1%	$9.5M-10.1%	$10.5M
Gross Profit	$24.1M-18.3%	$29.5M+12.1%	$26.3M-3.8%	$27.3M-10.2%	$30.4M-0.4%	$30.6M+30.8%	$23.4M-8.4%	$25.5M
R&D Expenses	$2.4M-36.3%	$3.7M+8.0%	$3.5M+18.3%	$2.9M+28.7%	$2.3M-28.3%	$3.2M-28.8%	$4.5M+0.7%	$4.4M
SG&A Expenses	$12.1M-9.7%	$13.5M-3.8%	$14.0M-3.4%	$14.5M+13.9%	$12.7M+4.6%	$12.1M-1.8%	$12.4M-11.0%	$13.9M
Operating Income	-$4.8M-12639.5%	$38K+100.9%	-$4.1M-150.0%	-$1.6M-151.9%	$3.2M-24.4%	$4.2M+193.6%	-$4.5M+30.8%	-$6.4M
Interest Expense	$3.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$8.1M-194.0%	-$2.8M+84.2%	-$17.5M-634.8%	-$2.4M-190.4%	$2.6M-18.7%	$3.2M+166.9%	-$4.8M+47.5%	-$9.2M
EPS (Diluted)	$-0.04	N/A	$-0.10-400.0%	$-0.02-300.0%	$0.01	N/A	$-0.03+50.0%	$-0.06

HRTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$255.9M+9.7%	$233.1M+4.8%	$222.5M-11.3%	$251.0M-17.9%	$305.7M-13.5%	$353.6M
Current Assets	$238.1M+13.9%	$209.0M+10.7%	$188.8M-8.1%	$205.4M-19.3%	$254.4M-19.0%	$314.2M
Cash & Equivalents	$28.6M+11.0%	$25.8M-10.0%	$28.7M+86.7%	$15.4M-83.0%	$90.5M-13.9%	$105.1M
Inventory	$92.7M+74.5%	$53.2M+26.2%	$42.1M-22.8%	$54.6M+12.8%	$48.4M+15.5%	$41.9M
Accounts Receivable	$89.6M+13.6%	$78.9M+31.2%	$60.1M+15.5%	$52.0M+46.6%	$35.5M-15.2%	$41.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$241.5M-9.5%	$266.8M+4.0%	$256.5M+8.0%	$237.4M+4.1%	$228.1M+94.9%	$117.1M
Current Liabilities	$96.1M+5.1%	$91.5M+14.8%	$79.7M-3.2%	$82.4M+15.9%	$71.1M-30.7%	$102.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$14.3M+142.6%	-$33.7M+0.9%	-$34.0M-350.3%	$13.6M-82.5%	$77.6M-67.2%	$236.5M
Retained Earnings	-$1.9B-1.1%	-$1.9B-0.7%	-$1.9B-6.2%	-$1.8B-11.3%	-$1.6B-15.8%	-$1.4B

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$246.2M-3.8%	$255.9M+2.8%	$248.9M+7.3%	$232.1M-1.6%	$235.8M+1.1%	$233.1M+5.6%	$220.8M+1.2%	$218.1M
Current Assets	$229.0M-3.8%	$238.1M+3.8%	$229.4M+8.8%	$210.9M-0.9%	$212.8M+1.8%	$209.0M+7.1%	$195.2M+2.1%	$191.2M
Cash & Equivalents	$26.1M-8.8%	$28.6M-33.5%	$43.1M+160.8%	$16.5M-14.3%	$19.3M-25.3%	$25.8M+0.2%	$25.7M+40.0%	$18.4M
Inventory	$92.5M-0.2%	$92.7M+32.4%	$70.0M-4.0%	$73.0M+28.2%	$56.9M+7.1%	$53.2M+15.7%	$46.0M+7.2%	$42.9M
Accounts Receivable	$83.7M-6.6%	$89.6M+10.5%	$81.0M+1.4%	$79.9M+1.5%	$78.7M-0.2%	$78.9M+17.7%	$67.0M-9.0%	$73.7M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$237.1M-1.8%	$241.5M+3.2%	$234.1M-9.7%	$259.3M-1.8%	$264.2M-1.0%	$266.8M+2.3%	$260.8M+1.8%	$256.1M
Current Liabilities	$90.5M-5.8%	$96.1M+7.1%	$89.7M-65.3%	$258.6M+192.0%	$88.6M-3.2%	$91.5M+6.9%	$85.5M+6.5%	$80.3M
Long-Term Debt	$108.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.1M-36.3%	$14.3M-3.7%	$14.9M+154.6%	-$27.3M+4.2%	-$28.5M+15.4%	-$33.7M+15.9%	-$40.0M-5.4%	-$37.9M
Retained Earnings	-$1.9B-0.4%	-$1.9B-0.2%	-$1.9B-0.9%	-$1.9B-0.1%	-$1.9B+0.1%	-$1.9B+0.2%	-$1.9B-0.3%	-$1.9B

HRTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$27.6M-22.5%	-$22.5M+61.7%	-$58.8M+60.0%	-$146.9M+27.8%	-$203.4M-10.0%	-$184.8M
Capital Expenditures	$317K-81.4%	$1.7M+10.4%	$1.5M-15.3%	$1.8M-39.6%	$3.0M-55.6%	$6.8M
Free Cash Flow	-$27.9M-15.2%	-$24.2M+59.8%	-$60.3M+59.4%	-$148.7M+27.9%	-$206.4M-7.7%	-$191.6M
Investing Cash Flow	$16.0M-14.5%	$18.7M+4.0%	$18.0M+641.4%	-$3.3M-110.2%	$32.7M-84.3%	$209.0M
Financing Cash Flow	$14.4M+1434.8%	$940K-98.3%	$54.1M-27.9%	$75.1M-51.9%	$156.0M+1613.7%	$9.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$1.5M+83.2%	-$9.2M-790.0%	$1.3M+112.2%	-$10.9M-22.5%	-$8.9M+24.7%	-$11.8M-449.5%	$3.4M+173.2%	-$4.6M
Capital Expenditures	$391K	$0	$0-100.0%	$208K+90.8%	$109K-82.9%	$638K+48.0%	$431K	N/A
Free Cash Flow	-$1.9M+79.0%	-$9.2M-790.0%	$1.3M+112.0%	-$11.1M-23.4%	-$9.0M+27.7%	-$12.4M-522.4%	$2.9M	N/A
Investing Cash Flow	-$939K+82.8%	-$5.5M-146.0%	$11.9M+61.7%	$7.3M+222.7%	$2.3M-80.1%	$11.4M+187.6%	$4.0M+93.8%	$2.0M
Financing Cash Flow	-$51K-123.3%	$219K-98.4%	$13.4M+1611.0%	$781K+1120.3%	$64K-84.9%	$423K+2921.4%	$14K-97.2%	$492K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HRTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	73.3%+0.1pp	73.2%+24.5pp	48.8%-0.3pp	49.0%+2.3pp	46.7%-12.5pp	59.2%
Operating Margin	-1.6%+6.3pp	-8.0%+79.1pp	-87.1%+75.1pp	-162.2%+90.1pp	-252.3%+5.1pp	-257.4%
Net Margin	-12.9%-3.2pp	-9.7%+77.7pp	-87.4%+81.7pp	-169.0%+86.9pp	-255.9%+0.5pp	-256.4%
Return on Equity	-139.5%	N/A	N/A	-1341.0%-1056.1pp	-284.9%-188.8pp	-96.1%
Return on Assets	-7.8%-1.8pp	-6.0%+43.9pp	-49.9%+22.6pp	-72.5%-0.2pp	-72.3%-8.0pp	-64.3%
Current Ratio	2.48+0.2	2.29-0.1	2.37-0.1	2.49-1.1	3.58+0.5	3.07
Debt-to-Equity	16.85+24.8	-7.93-0.4	-7.55-25.0	17.49+14.5	2.94+2.4	0.49
FCF Margin	-18.0%-1.2pp	-16.8%+30.7pp	-47.5%+90.6pp	-138.1%+100.9pp	-239.0%-22.8pp	-216.2%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	69.3%-3.3pp	72.6%+3.8pp	68.8%-4.7pp	73.5%-4.8pp	78.3%+3.3pp	74.9%+3.7pp	71.2%+0.4pp	70.8%
Operating Margin	-13.7%-13.8pp	0.1%+10.8pp	-10.7%-6.3pp	-4.4%-12.5pp	8.1%-2.1pp	10.2%+23.8pp	-13.6%+4.3pp	-17.9%
Net Margin	-23.4%-16.6pp	-6.8%+39.0pp	-45.8%-39.4pp	-6.4%-13.2pp	6.8%-1.2pp	8.0%+22.7pp	-14.8%+10.9pp	-25.6%
Return on Equity	-88.8%-69.5pp	-19.2%+98.3pp	-117.5%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-3.3%-2.2pp	-1.1%+5.9pp	-7.0%-6.0pp	-1.0%-2.1pp	1.1%-0.3pp	1.4%+3.6pp	-2.2%+2.0pp	-4.2%
Current Ratio	2.53+0.1	2.48-0.1	2.56+1.7	0.82-1.6	2.40+0.1	2.290.0	2.28-0.1	2.38
Debt-to-Equity	25.95+9.1	16.85+1.1	15.72+25.2	-9.51-0.2	-9.29-1.4	-7.93-1.4	-6.52+0.2	-6.75
FCF Margin	-5.6%+17.1pp	-22.6%-26.1pp	3.5%+33.3pp	-29.8%-6.7pp	-23.1%+7.4pp	-30.4%-39.4pp	9.0%	N/A

Similar Companies

Mediwound MDWD

$189.1M

Eupraxia Pharmac EPRX

$451.4M

NeOnc Technologies Holdings Inc NTHI

$116.4M

Entrada Therapeutics, Inc. TRDA

$287.3M

Sellas Life Sciences Group Inc SLS

$2.7B

Frequently Asked Questions

What is Heron Therapeutics Inc's annual revenue?

Heron Therapeutics Inc (HRTX) reported $154.9M in total revenue for fiscal year 2025. This represents a 7.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Heron Therapeutics Inc's revenue growing?

Heron Therapeutics Inc (HRTX) revenue grew by 7.4% year-over-year, from $144.3M to $154.9M in fiscal year 2025.

Is Heron Therapeutics Inc profitable?

No, Heron Therapeutics Inc (HRTX) reported a net income of -$20.0M in fiscal year 2025, with a net profit margin of -12.9%.

What is Heron Therapeutics Inc's EBITDA?

Heron Therapeutics Inc (HRTX) had EBITDA of -$224K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Heron Therapeutics Inc's gross margin?

Heron Therapeutics Inc (HRTX) had a gross margin of 73.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Heron Therapeutics Inc's operating margin?

Heron Therapeutics Inc (HRTX) had an operating margin of -1.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Heron Therapeutics Inc's net profit margin?

Heron Therapeutics Inc (HRTX) had a net profit margin of -12.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Heron Therapeutics Inc's return on equity (ROE)?

Heron Therapeutics Inc (HRTX) has a return on equity of -139.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Heron Therapeutics Inc's free cash flow?

Heron Therapeutics Inc (HRTX) generated -$27.9M in free cash flow during fiscal year 2025. This represents a -15.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Heron Therapeutics Inc's operating cash flow?

Heron Therapeutics Inc (HRTX) generated -$27.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Heron Therapeutics Inc's total assets?

Heron Therapeutics Inc (HRTX) had $255.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Heron Therapeutics Inc's capital expenditures?

Heron Therapeutics Inc (HRTX) invested $317K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Heron Therapeutics Inc spend on research and development?

Heron Therapeutics Inc (HRTX) invested $12.4M in research and development during fiscal year 2025.

How many shares does Heron Therapeutics Inc have outstanding?

Heron Therapeutics Inc (HRTX) had 189M shares outstanding as of fiscal year 2025.

What is Heron Therapeutics Inc's current ratio?

Heron Therapeutics Inc (HRTX) had a current ratio of 2.48 as of fiscal year 2025, which is generally considered healthy.

What is Heron Therapeutics Inc's debt-to-equity ratio?

Heron Therapeutics Inc (HRTX) had a debt-to-equity ratio of 16.85 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Heron Therapeutics Inc's return on assets (ROA)?

Heron Therapeutics Inc (HRTX) had a return on assets of -7.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Heron Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Heron Therapeutics Inc (HRTX) had $28.6M in cash against an annual operating cash burn of $27.6M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Heron Therapeutics Inc's Altman Z-Score?

Heron Therapeutics Inc (HRTX) has an Altman Z-Score of -9.17, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Heron Therapeutics Inc's Piotroski F-Score?

Heron Therapeutics Inc (HRTX) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Heron Therapeutics Inc's earnings high quality?

Heron Therapeutics Inc (HRTX) has an earnings quality ratio of 1.38x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Heron Therapeutics Inc cover its interest payments?

Heron Therapeutics Inc (HRTX) has an interest coverage ratio of -0.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Heron Therapeutics Inc?

Heron Therapeutics Inc (HRTX) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.